Phase 2 Trial of SAR443820 (RIPK1 Inhibitor) in Relapsing and Progressive Multiple Sclerosis: K2 Study Design and Baseline Characteristics

Category Primary study
ConferenceThe 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Year 2024
This article has no abstract
Epistemonikos ID: 2c03b801a3cb4ec1dc77bdab3f2e6188bb3cf7b6
First added on: Apr 04, 2026